Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01565343 · ClinicalTrials.gov registry record · Phase 1
A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers
A Phase 1 study of Alzheimers Disease, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 4
- Study locations
NCT01565343 is a Phase 1 study of Alzheimers Disease that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 25 participants, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT01565343, a Phase 1 study of Alzheimers Disease, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will test if two AV-45 PET scans up to 4 weeks apart in AD subjects and healthy volunteers provide the same results. The study will also test two different AV-45 injection methods in a small subgroup of enrolled AD subjects (slow vs. fast bolus group).
Conditions Studied
Interventions
- DRUG florbetapir F 18
Study Locations (4)
Florida
- Research Site - Hallandale
- Research Site - West Palm Beach
Connecticut
- Research Site - New Haven
Maryland
- Research Site - North East
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-04 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01565343
The ClinicalTrials.gov registry entry for NCT01565343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,061-participant average among 142 other Alzheimers Disease trials with a reported enrollment target (99% lower). The listed sponsor is Avid Radiopharmaceuticals, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT01565343 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, Connecticut, Maryland.
Frequently Asked Questions
What is clinical trial NCT01565343 about?
NCT01565343 is a clinical study titled "A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers". This study will test if two AV-45 PET scans up to 4 weeks apart in AD subjects and healthy volunteers provide the same results. The study will also test two different AV-45 injection methods in a small subgroup of enrolled AD subjects (slow vs. fast bolus group).
What is the current status of trial NCT01565343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-04. Estimated completion is 2009-04.
What conditions does trial NCT01565343 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01565343?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT01565343?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01565343 being conducted?
This trial has 4 study locations across Connecticut, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.